| No information of Name |
| Description | BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |